- Home
- BFST vs GERN Comparison
BFST vs GERN Comparison
Compare BFST & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BFST | GERN |
|---|---|---|
| Founded | 2006 | 1990 |
| Country | United States | United States |
| Employees | N/A | 229 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 948.1M | 1.1B |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | BFST | GERN |
|---|---|---|
| Price | $27.31 | $1.42 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 3 |
| Target Price | ★ $32.75 | $2.17 |
| AVG Volume (30 Days) | 136.9K | ★ 15.7M |
| Earning Date | 04-27-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.23% | N/A |
| EPS Growth | ★ 23.45 | N/A |
| EPS | ★ 0.68 | N/A |
| Revenue | ★ $10,704,000.00 | N/A |
| Revenue This Year | $22.71 | $26.91 |
| Revenue Next Year | $5.02 | $43.75 |
| P/E Ratio | $39.72 | ★ N/A |
| Revenue Growth | ★ 1.20 | N/A |
| 52 Week Low | $22.56 | $1.04 |
| 52 Week High | $30.32 | $2.01 |
Technical Indicators
Market Signals| Indicator | BFST | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 46.95 | 40.28 |
| Support Level | $26.78 | $1.24 |
| Resistance Level | $28.18 | $1.49 |
| Average True Range (ATR) | 0.61 | 0.09 |
| MACD | -0.07 | -0.01 |
| Stochastic Oscillator | 34.17 | 15.07 |
Price Performance
Historical ComparisonAbout BFST Business First Bancshares Inc.
Business First Bancshares Inc is a bank holding company. The company's services include personal and commercial banking, treasury management, and wealth solutions. It provides a range of financial services to small-to-midsized businesses and professionals. The company generates the majority of its revenues from interest income on loans, customer service and loan fees, and interest income from securities.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.